| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1371658 | Bioorganic & Medicinal Chemistry Letters | 2010 | 4 Pages |
Abstract
A series of aryl-substituted nicotinamide derivatives with selective inhibitory activity against the Nav1.8 sodium channel is reported. Replacement of the furan nucleus and homologation of the anilide linker in subtype-selective blocker A-803467 (1) provided potent, selective derivatives with improved aqueous solubility and oral bioavailability. Representative compounds from this series displayed efficacy in rat models of inflammatory and neuropathic pain.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Michael E. Kort, Robert N. Atkinson, James B. Thomas, Irene Drizin, Matthew S. Johnson, Matthew A. Secrest, Robert J. Gregg, Marc J.C. Scanio, Lei Shi, Ahmed H. Hakeem, Mark A. Matulenko, Mark L. Chapman, Michael J. Krambis, Dong Liu, Char-Chang Shieh,